September 1, 2020

Philips Introduces Next-Generation Azurion Image-Guided Therapy Platform

September 1, 2020—Royal Philips announced the introduction of the next-generation Philips Azurion image-guided therapy platform for interventional procedures.

The company stated that this new version of the Azurion platform integrates all the essential lab systems and tools to enhance clinician focus and control during procedures. Additionally, with the next-generation Azurion platform, Philips is introducing SmartCT, which guides users through the acquisition of three-dimensional (3D) CT-like images and can review and interact with the acquired CT-like 3D images on the tableside touch screen module using 3D visualization and measurement tools. These tools have been designed to support procedures in a range of clinical domains, including neurology, oncology, and cardiovascular procedures. SmartCT is not available for sale in the United States, where FDA 510(k) clearance is pending, advised the company.

The platform is available in three versions: the Azurion 3, Azurion 7, and, now, Azurion 5. The first Azurion platform was introduced in 2017.

According to Royal Philips, the latest Azurion platform integrates control of imaging, physiology, hemodynamic, and informatics applications, as well as intuitive control of the gantry, at the tableside, allowing clinicians to control all compatible applications from a single touch screen while performing procedures. This can eliminate the need for clinicians to leave the sterile field and step into an adjacent control room and supports faster and better-informed decision making.

Additionally, clinicians can switch easily between imaging, physiology, hemodynamic, and informatics applications, including SmartCT and IntraSight—a suite of instant wave-free ratio (iFR), fractional flow reserve, intravascular ultrasound (IVUS), and coregistration modalities.

Fully automatic position control enables clinicians to intuitively control the position of the gantry and table and control from a wide range of stored parameters. The new Azurion also includes advanced cybersecurity features, new high-definition image display capabilities, and remote and proactive services, stated the company.

“The integrated platform enables us to efficiently carry out complex interventions at any time using a wide range of functions such as IVUS and iFR coregistration,” commented Alexander Becker, MD, in the company’s press release. “The use of the control panel by the examiner is intuitive, combining different sources of information to make patient evaluation much easier and faster.” Dr. Becker is Head of the Cardiac Catheterization Laboratory at the Robert Bosch Hospital in Stuttgart, Germany, which is one of the first hospitals to experience the new platform.


September 2, 2020

ACC.21 Conference in Atlanta Rescheduled for May

September 1, 2020

CMS Proposed Rule Seeks to Accelerate Coverage and Access for FDA’s Designated Breakthrough Devices